Aberrant histone modification in endometriosis

Frontiers in Bioscience - Landmark

Volumn 19, Issue 8, 2014, Pages 1202-1214

  Nasu, Kaei ^a,b   Kawano, Yukie ^a   Kai, Kentaro ^a   Aoyagi, Yoko ^a   Abe, Wakana ^a   Okamoto, Mamiko ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Endometriosis; Epigenetics; Histone deacetylase; Histone deacetylase inhibitor; Histone modification; Review

Indexed keywords

HISTONE;

ACETYLATION; BIOLOGICAL MODEL; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM;

ACETYLATION; ENDOMETRIOSIS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; MODELS, GENETIC;

EID: 84904543815     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4276     Document Type: Article

References (129)

1. Giudice, L. C. & L. C. Kao: Endometriosis. Lancet, 364, 1789-1799 (2004) (Pubitemid 39488065)
2. Nasu, K., M. Nishida, Y. Kawano, A. Tsuno, W. Abe, A. Yuge, N. Takai & H. Narahara: Aberrant expression of apoptosis-related molecules in endometriosis: a possible mechanism underlying the pathogenesis of endometriosis. Reprod Sci, 18, 206-218 (2011)
3. Shin, J. C., H. L. Ross, S. Elias, D. D. Nguyen, D. Mitchell-Leef, J. L. Simpson & F. Z. Bischoff: Detection of chromosomal aneuploidy in endometriosis by multicolor fluorescence in situ hybridization (FISH). Hum Genet, 100, 401-406 (1997) (Pubitemid 27386848)
4. Gogusev, J., J. Bouquet de Joliniere, L. Telvi, M. Doussau, S. du Manoir, A. Stojkoski & M. Levardon: Detection of DNA copy number changes in human endometriosis by comparative genomic hybridization. Hum Genet, 105, 444-451 (1999)
5. Goumenou, A. G., D. A. Arvanitis, I. M. Matalliotakis, E. E. Koumantakis & D. A. Spandidos: Microsatellite DNA assays reveal an allelic imbalance in p16 (Ink4), GALT, p53, and APOA2 loci in patients with endometriosis. Fertil Steril, 75, 160-165 (2001) (Pubitemid 32041239)
6. Bischoff, F. Z., M. Heard & J. L. Simpson: Somatic DNA alterations in endometriosis: high frequency of chromosome 17 and p53 loss in late-stage endometriosis. J Reprod Immunol, 55, 49-64 (2002) (Pubitemid 34626151)
7. Reik, W., W. Dean & J. Walter: Epigenetic reprogramming in mammalian development. Science, 293, 1089-1093 (2001) (Pubitemid 32758081)
8. Goldberg, A. D. & C. D. Allis: Bernstein E. Epigenetics: a landscape takes shape. Cell, 128, 635-638 (2007) (Pubitemid 46273578)
9. Jenuwein, T. & C. D. Allis: Translating the histone code. Science, 293, 1074-1080 (2001) (Pubitemid 32758077)
10. Jones, P. A. & S. B. Baylin: The fundamental role of epigenetic events in cancer. Nat Rev Genet, 3, 415-428 (2002) (Pubitemid 34587077)
11. Bartel, D. P: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297 (2004)
12. Pazin, M. J. & J. T. Kadonaga: What's up and down with histone deacetylation and transcription? Cell, 89, 325-328 (1997) (Pubitemid 27220876)
13. Takai, N. & H. Narahara: Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem, 14, 2548-2553 (2007) (Pubitemid 350018467)
14. Kawano, Y., K. Nasu, H. Li, A. Tsuno, W. Abe, N. Takai & H. Narahara: Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target. Hum Reprod, 26, 2486-2498 (2011)
15. Nasu, K., Y. Kawano, Y. Tsukamoto, M. Takano, N. Takai, H. Li, Y. Furukawa, W. Abe, M. Moriyama & H. Narahara: Aberrant DNA methylation status of endometriosis: epigenetics as the pathogenesis, biomarker and therapeutic target. J Obstet Gynaecol Res, 37, 683-695 (2011)
16. Abe, W., K. Nasu, C. Nakada, Y. Kawano, M. Moriyama & H. Narahara: miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells. Hum Reprod, 28, 750-761 (2013)
17. Kawano, Y., K. Nasu, N. Hijiya, Y. Tsukamoto, K. Amada, W. Abe, K. Kai, M. Moriyama & H. Narahara: CCAAT/enhancer-binding protein α is epigenetically silenced by histone deacetylation in endometriosis and promotes the pathogenesis of endometriosis. J Clin Endocrinol Metab, 98, E1474-E1482 (2013)
18. Wu, Y. & S. W. Guo: Suppression of IL-1β-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol, 135, 88-93 (2007) (Pubitemid 350026147)
19. Lu, Y., J. Nie, X. Liu, Y. Zheng & S. W. Guo: Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod, 25, 1014-1025 (2010)
20. Wu, Y., A. Starzinski-Powitz & S.-W. Guo: Constitutive and Tumor Necrosis Factor-Alpha-Stimulated Activation of Nuclear Factor-KappaB in Immortalized Endometriotic Cells and Their Suppression by Trichostatin A. Gynecol Obstet Invest, 70, 23-33 (2010)
21. Monteiro, J. B., M. Colón-Díaz, M. García, S. Gutierrez, M. Colón, E. Seto, J. Laboy & I. Flores: Endometriosis is characterized by a distinct pattern of histone 3 and histone 4 lysine modifications. Reprod Sci, (Epub ahead of print) (2013)
22. Xiaomeng, X., Z. Ming, M. Jiezhi & F. Xiaoling: Aberrant histone acetylation and methylation levels in woman with endometriosis. Arch Gynecol Obstet, 287, 487-494 (2013)
23. Cress, W. D. & E. Seto: Histone deacetylases, transcriptional control, and cancer. J Cell Physiol, 184, 1-16 (2000) (Pubitemid 30349623)
24. Bertrand, P: Inside HDAC with HDAC inhibitors. Eur J Med Chem, 45, 2095-2116 (2010)
25. Munro, S. K., C. M. Farquhar, M. D. Mitchell & A. P. Ponnampalam: Epigenetic regulation of endometrium during the menstrual cycle. Mol Hum Reprod, 16, 297-310 (2010)
26. De Ruijter, A. J., A. H. van Gennip, H. N. Caron, S. Kemp & A. B. van Kuilenburg: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 370, 737-749 (2003) (Pubitemid 36399066)
27. Peinado, H., E. Ballestar, M. Esteller & A. Cano: Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol, 24, 306-319 (2004) (Pubitemid 38010056)
28. Grzenda, A., G. Lomberk, J. S. Zhang & R. Urrutia: Sin3: master scaffold and transcriptional corepressor. Biochim Biophys Acta, 1789, 443-450 (2009)
29. Hayashi, A., A. Horiuchi, N. Kikuchi, T. Hayashi, C. Fuseya, A. Suzuki, I. Konishi & T. Shiozawa: Typespecific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer, 127, 1332-1346 (2010)
30. Wilting, R. H., E. Yanover, M. R. Heideman, H. Jacobs, J. Horner, J. van der Torre, R. A. DePinho & J. H. Dannenberg: Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J, 29, 2586-2597 (2010)
31. Yamaguchi, T., F. Cubizolles, Y. Zhang, N. Reichert, H. Kohler, C. Seiser & P. Matthias: Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev, 24, 455-469 (2010)
32. Krusche, C. A., A. J. Vloet, I. Classen-Linke, U. von Rango, H. M. Beier & J. Alfer: Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod, 22, 2956-2966 (2007) (Pubitemid 351696801)
33. Colón-Díaz, M., P. Báez-Vega, M. García, A Ruiz, J. B. Monteiro, J. Fourquet, M. Bayona, C. Alvarez-Garriga, A. Achille, E. Seto, & I. Flores: HDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod Sci, 19, 483-492 (2012)
34. Samartzis, E. P., A. Noske, N. Samartzis, D. Fink & P. Imesch: The Expression of Histone Deacetylase 1, But Not Other Class I Histone Deacetylases, Is Significantly Increased in Endometriosis. Reprod Sci, (Epub ahead of print) (2013)
35. Brandenberger, A. W., D. I. Lebovic, M. K. Tee, I. P. Ryan., J. F. Tseng, R. B. Jaffe & R. N. Taylor: Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod, 5, 651-655 (1999) (Pubitemid 29317755)
36. Fujimoto, J., R. Hirose, H. Sakaguchi & T. Tamaya: Expression of oestrogen receptor-alpha and -beta in ovarian endometriomata. Mol Hum Reprod, 5, 742-747 (1999) (Pubitemid 29366872)
37. Xue, Q., Z. Lin, Y. H. Cheng, C. C. Huang, E. Marsh, P. Yin, M. P. Milad, E. Confino, S. Reierstad, J. Innes & S. E. Bulun: Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod, 77, 681-687 (2007) (Pubitemid 47494383)
38. Kuiper, G. G., B. Carlsson, K. Grandien, E. Enmark, J. Häggblad, S. Nilsson & J. A. Gustafsson: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 138, 863-870 (1997) (Pubitemid 27089735)
39. Tong, W., R. Perkins, L. Xing, W. J. Welsh & D. M. Sheehan: QSAR models for binding of estrogenic compounds to estrogen receptor alpha and beta subtypes. Endocrinology, 138, 4022-4025 (1997) (Pubitemid 27351959)
40. Prossnitz, E. R., & M. Maggiolini: Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol, 308, 32-38 (2009)
41. Maggiolini, M. & D. Picard: The unfolding stories of GPR30, a new membranebound estrogen receptor. J Endocrinol, 204, 105-114 (2010)
42. Samartzis, N., E. P. Samartzis, A. Noske, A. Fedier, K. J. Dedes, R. Caduff, D. Fink & P. Imesch: Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis: a tissue microarray study. Reprod Biol Endocrinol, 10:30 (2012)
43. Heublein, S., M. Lenhard, T. Vrekoussis, J. Schoepfer, C. Kuhn, K. Friese, D. Mayr, A. Makrigiannakis & U. Jeschke: The G-protein coupled estrogen receptor (GPER) is expressed in normal human ovaries and is upregulated in ovarian endometriosis and pelvic inflammatory disease involving the ovary. Reprod Sci, 19, 1197-1204 (2012)
44. Imesch P., E. P. Samartzis, K. J. Dedes, D. Fink & A. Fedier: Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells. Fertil Steril, 100, 770-776 (2013)
45. Rice, D. A., A. R. Mouw, A. M. Bogerd & K. L. Parker: A shared promoter element regulates the expression of three steroidogenic enzymes. Mol Endocrinol, 5, 1552-1561 (1991)
46. Morohashi, K., S. Honda, Y. Inomata, H. Handa & T. Omura: A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. J Biol Chem, 267, 17913-17919 (1992)
47. Zeitoun, K., K. Takayama, M. D. Michael & S. E. Bulun: Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol, 13, 239-253 (1999) (Pubitemid 29067999)
48. Xue, Q., Z. Lin, P. Yin, M. P. Milad, Y.-H. Cheng, E. Confino, S. Reierstad & S. E. Bulun: Transcriptional Activation of steroidogenic factor-1 by hypomethylation of the 5' CpG island in endometriosis. J Clin Endocrinol Metab, 92, 3261-3232 (2007)
49. Gehring W. J: Homeo boxes in the study of development. Science, 236, 1245-1252 (1987) (Pubitemid 17087888)
50. Taylor, H. S., A. Arici, D. Olive & P. Igarashi: HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. J Clin Invest, 101, 1379-1384 (1998) (Pubitemid 28166835)
51. Taylor, H. S., C. Bagot, A. Kardana, D. Olive & A. Arici: HOX gene expression is altered in the endometrium of women with endometriosis. Hum Reprod, 14, 1328-1331 (1999) (Pubitemid 29224916)
52. Gui, Y., J. Zhang, L. Yuan & B. A. Lessey: Regulation of HOXA-10 is and its expression in normal and abnormal endometrium. Mol Hum Reprod, 5, 866-873 (1999) (Pubitemid 29406751)
53. Wu, Y., G. Halverson, Z. Basir, E. Strawn, P. Yan & S. W. Guo: Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol, 193, 371-380 (2005) (Pubitemid 41159530)
54. Ramji, D. P. & P. Foka: CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J, 365, 561-575 (2002) (Pubitemid 34864439)
55. Yang, S., Z. Fang, T. Suzuki, H. Sasano, J. Zhou, B. Gurates, M. Tamura, K. Ferrer & S. Bulun: Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase. J Clin Endocrinol Metab, 87, 2336-2345 (2002) (Pubitemid 34521528)
56. Wu, M. H., K. F. Chen, S. C. Lin, C. W. Lgu & S. J. Tsai: Aberrant expression of leptin in human endometriotic stromal cells is induced by elevated levels of hypoxia inducible factor-1alpha. Am J Pathol, 170, 590-598 (2007)
57. Kim, S. H., J. W. Jeong, J. A. Park, J. W. Lee, J. H. Seo, B. K. Jung, M. K. Bae & K. W. Kim: Regulation of the HIF-1α stability by histone deacetylases. Oncol Rep, 17, 647-651 (2007)
58. Ellis, L., H. Hammers & R. Pili: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett, 280, 145-153 (2009)
59. Imesch, P., D. Fink & A. Fedier: Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil Steril, 94, 2838-2842 (2010)
60. Imesch, P., E. P. Samartzis, M. Schneider, D. Fink & A. Fedier: Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. Fertil Steril, 95, 1579-1583 (2011)
61. Serrano, M., G. J. Hannon & D. Beach: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707 (1993) (Pubitemid 24036021)
62. Lowe, S. W. & C. J. Sherr: Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev, 13, 77-83 (2003) (Pubitemid 36143931)
63. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks & G. J. Hannon: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 377, 552-557 (1995)
64. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82, 675-684 (1995)
65. Takai, N., M. Kawamata, D. Gui, J. W. Said, I. Miyakawa & H. P. Koeffler: Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer, 101, 2760-2770 (2004) (Pubitemid 39603184)
66. Chen, J., P. K. Jackson, M. W. Kirschner & A. Dutta: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 374, 386-388 (1995)
67. Cip1. Nature, 375, 159-161 (1995)
68. Moldovan, G. L., B. Pfander & S. Jentsch: PCNA, the maestro of the replication fork. Cell, 129, 665-679 (2007) (Pubitemid 46802385)
69. Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene, 16, 217-225 (1998) (Pubitemid 28045108)
70. Smits, V. A., R. Klompmaker, T. Vallenius, G. Rijksen, T. P. Mäkela & R. H. Medema: p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem, 275, 30638-30643 (2000)
71. Abbas, T., S. Jha, N. E. Sherman & A. Dutta: Autocatalytic phosphorylation of CDK2 at the activating Thr160. Cell Cycle, 6, 843-852 (2007) (Pubitemid 46572627)
72. Katayose, Y., M. Kim, A. N. Rakkar, Z. Li, K. H. Cowan & P. Seth: Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res, 57, 5441-5445 (1997) (Pubitemid 28006743)
73. Keyomarsi, K., S. L. Tucker, T. A. Buchholz, M. Callister, Y. Ding, G. N. Hortobagyi, I. Bedrosian, C. Knickerbocker, W. Toyofuku, M. Lowe, T. W. Herliczek & S. S. Bacus: Cyclin E and survival in patients with breast cancer. N Engl J Med, 347, 1566-1575 (2002) (Pubitemid 35315837)
74. Bloom, J. & M. Pagano: Deregulated degradation of the CDK inhibitor p27 and malignant transformation. Semin Cancer Biol, 13, 41-47 (2003) (Pubitemid 36269179)
75. Chu, I. M., L. Hengst & J. M. Slingerland: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer, 8, 253-267 (2008) (Pubitemid 351430863)
76. Levkau, B., H. Koyama, E. W. Raines, B. E. Clurman, B. Herren, K. Orth, J. M. Roberts & R. Ross: Cleavage of p21Cip1/Waf1 and p27Kip1mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell, 1, 553-563 (1998) (Pubitemid 128374691)
77. Besson, A., S. F. Dowdy & J. M. Roberts: CDK inhibitors: cell cycle regulators and beyond. Dev Cell, 14, 159-169 (2008) (Pubitemid 351189186)
78. St Croix, B., V. A. Florenes, J. W. Rak, M. Flanagan, N. Bhattacharya, J. M. Slingerland & R. S. Kerbel: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med, 2, 1204-1210 (1996) (Pubitemid 26375403)
79. Chaturvedi, P., W. K. Eng, Y. Zhu, M. R. Mattern, R. Mishra, M. R. Hurle, X. Zhang, R. S. Annan, Q. Lu, L. F. Faucette, G. F. Scott, X. Li, S. A. Carr, R. K. Johnson, J. D. Winkler & B. B. Zhou: Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene, 18, 4047-4054 (1999) (Pubitemid 29363911)
80. Bartek, J. & J. Lukas: Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol, 13, 738-747 (2001) (Pubitemid 33042735)
81. Kato, N., H. Fujimoto, A. Yoda, I. Oishi, N. Matsumura, T. Kondo, J. Tsukada, Y. Tanaka, M. Imamura & Y. Minami: Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. Cell Death Differ, 11, S153-S161 (2004)
82. Chehab, N. H., A. Malikzay, M. Appel & T. D. Halazonetis: Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev, 14, 278-288 (2000) (Pubitemid 30106483)
83. Bartek, J. & J. Lukas: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-429 (2003) (Pubitemid 38340288)
84. Turnbull, C., S. Seal, A. Renwick, M. Warren-Perry, D. Hughes, A. Elliott, D. Pernet, S. Peock, J. W. Adlard, J. Barwell, J. Berg, A. F. Brady, C. Brewer, G. Brice, C. Chapman, J. Cook, R. Davidson, A. Donaldson, F. Douglas, L. Greenhalgh, A. Henderson, L. Izatt, A. Kumar, F. Lalloo, Z. Miedzybrodzka, P. J. Morrison, J. Paterson, M. Porteous, M. T. Rogers, S. Shanley, L. Walker; Breast Cancer Susceptibility Collaboration (UK), EMBRACE, M. Ahmed, D. Eccles, D. G. Evans, P. Donnelly, D. F. Easton, M. R. Stratton & N. Rahman: Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet, 21, 958-962 (2012)
85. Fuchs, P., S. Strehl, M. Dworzak, A. Himmler & P. F. Ambros: Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13. Genomics, 13, 219-224 (1992)
86. Behrmann, I., H. Walczak & P. H. Krammer: Structure of the human APO-1 gene. Eur J Immunol, 24, 3057-3062 (1994)
87. Chinnaiyan, A. M., K. O'Rourke, G. L. Yu, R. H. Lyons, M. Garg, D. R. Duan, L. Xing, R. Gentz, J. Ni & V. M. Dixit: Signal transduction by DR3, a death domaincontaining receptor related to TNFR-1 and CD95. Science, 274, 990-992 (1996) (Pubitemid 26398422)
88. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni & V. M. Dixit: The receptor for the cytotoxic ligand TRAIL. Science, 276, 111-113 (1997) (Pubitemid 27161256)
89. Pan, G., J. Ni, Y. F. Wei, G. Yu, R. Gentz & V. M. Dixit: An antagonist decoy receptor and a death domaincontaining receptor for TRAIL. Science, 277, 815-818 (1997) (Pubitemid 27366732)
90. Pan, G., J. H. Bauer, V. Haridas, S. Wang, D. Liu, G. Yu, C. Vincenz, B. B. Aggarwal, J. Ni & V. M. Dixit: Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett, 431, 351-356 (1998) (Pubitemid 28352389)
91. Smith, C. A., T. Farrah & R. G. Goodwin: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 76, 959-962 (1994) (Pubitemid 24106376)
92. Jeremias, I. & K. M. Debatin: TRAIL induces apoptosis and activation of NFkappaB. Eur Cytokine Netw, 9, 687-8 (1998) (Pubitemid 29033939)
93. Schulze-Osthoff K., D. Ferrari, M. Los, S. Wesselborg & E. Peter M: Apoptosis signaling by death receptors. Eur J Biochem, 254, 439-459 (1998) (Pubitemid 28308094)
94. Aggarwal, B. B: Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev Immunol, 3, 745-756 (2003) (Pubitemid 41070815)
95. Elrod, H. A. & S. Y. Sun: Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther, 7, 163-173 (2008) (Pubitemid 351590418)
96. Locksley, R. M., N. Killeen & M. J. Lenardo: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104, 487-501 (2001) (Pubitemid 32201945)
97. Bossen C., K. Ingold, A. Tardivel, J. L. Bodmer, O. Gaide, S. Hertig, C. Ambrose, J. Tschopp & P. Schneider: Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem, 281, 13964-13971 (2006) (Pubitemid 43848322)
98. Wilson, N. S., V. M. Dixit & A. Ashkenazi: Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol, 10, 348-355 (2009)
99. Liu, J., S. Na, A. Glasebrook, N. Fox, P. J. Solenberg, Q. Zhang, H. Y. Song & D. Yang: Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity, 15, 23-34 (2001) (Pubitemid 32728317)
100. Zhao, H., M. Yan, H. Wang, S. Erickson, I. S. Grewal, V. M. Dixit: Impaired c-Jun. amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med, 194, 1441-1448 (2001) (Pubitemid 33081519)
101. Schmidt, C. S., J. Liu, T. Zhang, H. Y. Song, G. Sandusky, K. Mintze, R. J. Benschop, A. Glasebrook, D. D. Yang & S. Na: Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J Exp Med, 197, 51-62 (2003) (Pubitemid 36110257)
102. Nikolaev, A., T. McLaughlin, D. D. O'Leary, M. Tessier-Lavigne: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature, 457, 981-989 (2009)
103. Mi, S., X. H. Lee, Y. H. Hu, B. X. Ji, Z. H. Shao, W. X. Yang, G. Huang, L. Walus, K. Rhodes, B. J. Gong, R. H. Miller & R. B. Pepinsky: Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. Nat Med, 17, 816-821 (2011)
104. Kai, K., K. Nasu, Y. Kawano, Y. Aoyagi, Y. Tsukamoto, N. Hijiya, W. Abe, M. Okamoto, M. Moriyama & H. Narahara: Death Receptor 6 is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis. Am J Reprod Immunol, 70, 485-496 (2013)
105. Gumbiner, B. M: Regulation of cadherin adhesive activity. J Cell Biol, 148, 399-404 (2000)
106. Frixen, U. H., J. Behrens, M. Sachs, G. Eberle, B. Voss, A. Warda, D. Löchner & W. Birchmeier: E-cadherinmediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol, 113, 173-185 (1991) (Pubitemid 21909684)
107. Starzinski-Powitz, A., R. Gaetje, A. Zeitvogel, S. Kotzian, H. Handrow-Metzmacher, G. Herrmann, E. Fanning & R. Baumann: Tracing cellular and molecular mechanisms involved in endometriosis. Hum Reprod Update, 4, 724-729 (1998) (Pubitemid 29041486)
108. Wu, Y., A. Starzinski-Powitz & S.-W. Guo: Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci, 14, 374-382 (2007) (Pubitemid 351168805)
109. Wu, Y., A. Starzinski-Powitz & S. W. Guo: Capsaicin inhibits proliferation of endometriotic cells in vitro. Gynecol Obstet Invest, 66, 59-62 (2008) (Pubitemid 352009133)
110. Practice Committee of the American Society for Reproductive Medicine: Endometriosis and infertility. Fertil Steril, 81, 1441-1446 (2004)
111. Nasu, K., A. Tsuno, A. Yuge, Y. Kawano & H. Narahara: Combined oral contraceptives for the medical treatment of endometriosis-associated pain. Recent Adv Endocrinol Metab, 1, 1-14 (2009)
112. Lessey, B. A: Medical management of endometriosis and infertility. Fertil Steril, 73, 1089-1096 (2000) (Pubitemid 30336748)
113. Bulun, S. E., Z. Lin, G. Imir, S. Amin, M. Demura, B. Yilmaz, R. Martin, H. Utsunomiya, S. Thung, B. Gurates, M. Tamura, D. Langoi & S. Deb: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev, 57, 359-383 (2005) (Pubitemid 41196955)
114. Bergqvist, A: A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecol Endocrinol, 14, 425-432 (2000) (Pubitemid 32165452)
115. Yoo, C. B. & P. A. Jones: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov, 5, 37-50 (2006)
116. Duenas-Gonzalez, A., M. Candelaria, C. Perez-Plascencia, E. Perez-Cardenas, E. de la Cruz-Hernandez & L. A. Herrera: Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev, 34, 206-222 (2008)
117. Mann, B. S., J. R. Johnson, K. He, R. Sridhara, S. Abraham, B. P. Booth, L. Verbois, D. E. Morse, J. M. Jee, S. Pope, R. S. Harapanhalli, R. Dagher, A. Farrell, R. Justice & R. Pazdur: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res, 13, 2318-2322 (2007) (Pubitemid 46698579)
118. Gerstner, T., N. Bell & S. Konig: Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Exp Opin Pharmacother, 9, 285-292 (2008) (Pubitemid 351233735)
119. Wu, Y & S. W. Guo: Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol, 137, 198-203 (2008) (Pubitemid 351423449)
120. Wu, Y., A. Starzinski-Powitz & S.-W. Guo: Prolonged stimulation with tumor necrosis factor-α induced partial methylation at PR-B promoter in immortalized epitheliallike endometriotic cells. Fertil Steril, 90, 234-237 (2008) (Pubitemid 351885197)
121. Wu, Y & S. W. Guo: Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertil Steril, 91 Suppl, 2142-2147 (2009)
122. Liu, M., X. Liu, Y. Zhang & S. W. Guo: Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci, 19, 360-373 (2012)
123. Liu, X & S. W. Guo: A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril, 89, 246-250 (2008)
124. Eyster, K. M., A. L. Boles, J. D. Brannian & K. A. Hansen: DNA microarray analysis of gene expression markers of endometriosis. Fertil Steril, 77, 38-42 (2002) (Pubitemid 34093890)
125. Kao, L. C., A. Germeyer, S. Tulac, S. Lobo, J. P. Yang, R. N. Taylor, K. Osteen, B. A. Lessey & L. C. Giudice: Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology, 144, 2870-2881 (2003) (Pubitemid 36819889)
126. Matsuzaki, S., M. Canis, J. L. Pouly, R. Botchorishvili, P. J. Dechelotte & G. Mage: Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis. Fertil Steril, 86, 548-553 (2006) (Pubitemid 44321907)
127. Flores, I., E. Rivera, L. A. Ruiz, O. I. Santiago, M. W. Vernon & C. B. Appleyard: Molecular profiling of experimental endometriosis identified gene expression patterns in common with human disease. Fertil Steril, 87, 1180-1199 (2007) (Pubitemid 46659936)
128. Konno, R., H. Fujiwara, S. Netsu, K. Odagiri, M. Shimane, H. Nomura & M. Suzuki: Gene expression profiling of the rat endometriosis model. Am J Reprod Immunol, 58, 330-343 (2007) (Pubitemid 47382231)
129. Guo, S. W: Epigenetics of endometriosis. Mol Hum Reprod, 15, 587-607 (2009)